Lineage Cell Therapeutics, Inc. splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Event Based Milestones And Other Collaborative Revenue at $7.2 million, 49% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13
|
15
|
9
|
9
|
15
|
4
|
2
|
4
|
5
|
3
|
6
|
| Collaboration Revenues |
—
|
—
|
8
+7.4%
share 85.8%
|
8
-43.2%
share 84.8%
|
13
share 90.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Event Based Milestones And Other Collaborative Revenue |
—
|
7
share 49.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Upfront License Fees |
—
|
6
-20.9%
share 44.3%
|
8
+7.4%
share 85.8%
|
8
-43.2%
share 84.8%
|
13
+2857.3%
share 90.9%
|
0
share 10.4%
|
—
|
—
|
—
|
—
|
—
|
| Royalty |
—
|
—
|
—
|
—
|
—
|
3
+259.1%
share 63.9%
|
1
share 42.3%
|
—
|
—
|
—
|
—
|
| Royalties |
—
|
—
|
—
|
1
+1.6%
share 15.2%
|
1
-51.9%
share 9.1%
|
3
+259.1%
share 63.9%
|
1
share 42.3%
|
—
|
—
|
—
|
—
|
| Royalties License And Other Revenues |
—
|
1
-29.9%
share 6.5%
|
1
-0.5%
share 14.2%
|
1
+1.6%
share 15.2%
|
1
share 9.1%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Grant Revenues |
—
|
—
|
—
|
—
|
—
|
0
-57.7%
share 10.3%
|
1
share 57.7%
|
—
|
—
|
—
|
—
|
| Event Based Development Milestones |
—
|
—
|
—
|
—
|
—
|
0
share 2.8%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LCTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 876343
- Former names
- BIOTIME INC (until Aug 8, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.